Assessing Risk Factors for Silent Myocardial Ischemia in Adults with Type 2 Diabetes: A Cross-Sectional Study
DOI:
https://doi.org/10.36283/ziun-pjmd14-4/041Keywords:
Myocardial Ischemia, Diabetes Mellitus, Type 2, Asymptomatic Diseases, Hypertension, Diabetic NephropathiesAbstract
Background: Silent myocardial ischemia (SMI) is an insidious but lethal form of coronary artery disease, especially in persons with type 2 diabetes mellitus (T2DM). It is often asymptomatic, which results in late diagnosis and risk of negative cardiac outcomes. The purpose of this study was to evaluate the prevalence and risk factors of SMI in adults having T2DM.
Methods: This cross-sectional study was conducted between February and July 2025 in the cardiology and endocrinology departments of a tertiary care facility. Non-probability purposive sampling was used to recruit 150 adults aged 35-70 years with a confirmed diagnosis of T2DM for more than five years. The participants were subjected to resting electrocardiography (ECG), treadmill stress test, and laboratory profiling of HbA1c, lipids, and renal tests. Statistical analysis with SPSS version 26.0 consisted of a chi-square test to compare categorical variables and logistic regression for confounder adjustment, where p < 0.05 was considered significant. Results: The prevalence of SMI was 58 (38.6%). The most significant relations observed were the duration of diabetes (10 years or more) (OR: 3.75; CI: 1.87-7.53), poor glycemic control (HbA1c above 8%) (OR: 3.37; CI: 1.69 – 6.71), hypertension (OR: 2.57; CI:1.24 – 5.31), and microalbuminuria (OR: 2.95; CI: 1.45 – 6.01). Dyslipidemia was nearly significant, whereas gender, BMI, and smoking were not relevant to SMI.
Conclusion: SMI is widespread in asymptomatic T2DM patients. Metabolic and renal risk markers could be identified to facilitate earlier screening and intervention to lower the risk of unrecognized cardiac outcomes.
References
1. Abdul Manan H, Chishti HR, Hewlett FD. Prevalence and Predictors of Silent Myocardial Ischemia in Diabetic Patients. Cureus. 2025 Apr 16;17(4):e82407. doi: 10.7759/cureus.82407.
2. Siddiq MZ, Memon SH, Ali A, Almas T, Razzaq A, Ahmed F. Diabetes Mellitus with Silent Myocardial Ischemia: A Single-Center Cross-Sectional Study of Karachi, Pakistan. J Pharm Res Int. 2021 May 24;56–60. doi: 10.9734/jpri/2021/v33i29B31589.
3. Zia N, Aftab S, Butt NI, Ashfaq F, Anser A, Saeed S. PREVALENCE OF SILENT CARDIAC ISCHEMIA IN TYPE II DIABETES MELLITUS. Pak. Heart J. 2021 Jun 24;54(2):162–6. doi: 10.47144/phj.v54i2.2093.
4. Hussain KSA. Prevalence and clinical predictors of silent myocardial ischemia in asymptomatic type 2 Diabetes Mellitus patients at Puducherry, India. Int J Adv Med. 2018 Jul 23;5(4):887. doi: 10.18203/2349-3933.ijam20182929.
5. Theofilis P, Antonopoulos AS, Sagris M, Papanikolaou A, Oikonomou E, Tsioufis K, et al. Silent Myocardial Ischemia: From Pathophysiology to Diagnosis and Treatment. Biomedicines. 2024 Jan 23;12(2):259. doi: 10.3390/biomedicines12020259.
6. Crasto W, Patel V, Davies MJ, Khunti K. Prevention of Microvascular Complications of Diabetes. Endocrinol Metab Clin North Am. 2021 Sep;50(3):431-455. doi: 10.1016/j.ecl.2021.05.005.
7. Valensi P, Berkane N, Pinto S, Sellier N, Soussan M, Nguyen MT, et al. Performance of the 2019 ESC/EASD guideline strategy for the screening of silent coronary artery disease in patients with diabetes. Cardiovasc Diabetol. 2023 Feb 15;22(1):33. doi: 10.1186/s12933-023-01760-4.
8. Mfeukeu-Kuate L, Meyanui VA, Jingi AM, Ndobo-Koe V, Mballa F, Ntep-Gweth M, et al. Prevalence and determinants of silent myocardial ischemia in patients with type 2 diabetes in Cameroon: a cross-sectional study. Pan Afr Med J. 2022 May 16;42:41. doi: 10.11604/pamj.2022.42.41.34941.
9. Arshad MM, Hassan MA, Tahir M, Nawaz Khan MS, Gultasib MA, Ali G. Evaluating Risk Factors and the Burden of Silent Myocardial Ischemia Among Diabetic Patients. Cureus. 2024 Nov 24;16(11):e74341. doi: 10.7759/cureus.74341.
10. Herman WH, Kuo S. Is Screening for Heart Failure and Peripheral Artery Disease Warranted in Asymptomatic Adults With Diabetes? A Perspective on the 2025 American Diabetes Association "Standards of Care in Diabetes". Diabetes Care. 2025 Jun 12:dci240103. doi: 10.2337/dci24-0103.
11. Bhardwaj R, Agrawal U, Vashist P, Manna S. Determination of sample size for various study designs in medical research: A practical primer. J Family Med Prim Care. 2024 Jul;13(7):2555-2561. doi: 10.4103/jfmpc.jfmpc_1675_23.
12. Sudo SZ, Montagnoli TL, Rocha BS, Santos AD, de Sá MPL, Zapata-Sudo G. Diabetes-Induced Cardiac Autonomic Neuropathy: Impact on Heart Function and Prognosis. Biomedicines. 2022 Dec 15;10(12):3258. doi: 10.3390/biomedicines10123258.
13. Han Y. Current clinical data and experience of TAVR in China. Eur Heart J. 2022 Jun 6;43(22):2087–8. doi: 10.1093/EURHEARTJ/EHAB82.
14. Wang M, Liu Y, Liang Y, Naruse K, Takahashi K. Systematic Understanding of Pathophysiological Mechanisms of Oxidative Stress-Related Conditions-Diabetes Mellitus, Cardiovascular Diseases, and Ischemia-Reperfusion Injury. Front Cardiovasc Med. 2021 Apr 13;8:649785. doi: 10.3389/fcvm.2021.649785.
15. Pietrangelo D, Lopa C, Litterio M, Cotugno M, Rubattu S, Lombardi A. Metabolic Disturbances Involved in Cardiovascular Diseases: The Role of Mitochondrial Dysfunction, Altered Bioenergetics and Oxidative Stress. Int. J. Mol. Sci. 2025 Jul 15;26(14):6791. doi: 10.3390/IJMS26146791.
16. Xiao M, Malmi MA Jr, Schocken DD, Zgibor JC, Alman AC. Longitudinal blood glucose level and increased silent myocardial infarction: a pooled analysis of four cohort studies. Cardiovasc Diabetol. 2024 Apr 18;23(1):130. doi: 10.1186/s12933-024-02212-3.
17. Zeng X, Yang Y. Molecular Mechanisms Underlying Vascular Remodeling in Hypertension. Rev Cardiovasc Med. 2024 Feb 20;25(2):72. doi: 10.31083/j.rcm2502072.
18. Humphrey JD. Mechanisms of Vascular Remodeling in Hypertension. Am J Hypertens. 2021 May 22;34(5):432-441. doi: 10.1093/ajh/hpaa195.
19. Fokoua-Maxime CD, Lontchi-Yimagou E, Cheuffa-Karel TE, Tchato-Yann TL, Pierre-Choukem S. Prevalence of asymptomatic or "silent" myocardial ischemia in diabetic patients: Protocol for a systematic review and meta-analysis. PLoS One. 2021 Jun 10;16(6):e0252511. doi: 10.1371/journal.pone.0252511.
20. Szabóová E, Lisovszki A, Fatľová E, Kolarčik P, Szabó P, Molnár T. Prevalence of Microalbuminuria and Its Association with Subclinical Carotid Atherosclerosis in Middle Aged, Nondiabetic, Low to Moderate Cardiovascular Risk Individuals with or without Hypertension. Diagnostics (Basel). 2021 Sep 19;11(9):1716. doi: 10.3390/diagnostics11091716.
21. Ahmed AA, Salama EH, Shehata HA. Ischemia-modified albumin relation to glycemic state, neuropathy, and retinopathy in patients with type2 Diabetes mellitus. SVU-International Journal of Medical Sciences. 2024 Jan 1;7(1):17-25. doi: 10.21608/SVUIJM.2022.167939.1431.
22. Lin L, Deng KQ, Chen Z, Lei F, Qin JJ, Huang X, et al. Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population. Atherosclerosis. 2023 May;372:1-9. doi: 10.1016/j.atherosclerosis.2023.03.007.
23. Lip GYH, Lane DA, Lenarczyk R, Boriani G, Doehner W, Benjamin LA, et al. Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. Eur Heart J. 2022 Jul 7;43(26):2442-2460. doi: 10.1093/eurheartj/ehac245.
24. Wazir M, Olanrewaju OA, Yahya M, Kumari J, Kumar N, Singh J, et al. Lipid Disorders and Cardiovascular Risk: A Comprehensive Analysis of Current Perspectives. Cureus. 2023 Dec 31;15(12):e51395. doi: 10.7759/cureus.51395.
25. Skolnik NS, Style AJ. Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes. Diabetes Ther. 2021 Jun;12(6):1613-1630. doi: 10.1007/s13300-021-01050-w.
26. Sachdeva P, Kaur K, Fatima S, Mahak F, Noman M, Siddenthi SM, et al. Advancements in Myocardial Infarction Management: Exploring Novel Approaches and Strategies. Cureus. 2023 Sep 19;15(9):e45578. doi: 10.7759/cureus.45578.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
